Advanced search
Publication Cover
Psychiatry and Clinical Psychopharmacology Volume 28, 2018 - Issue 2
Journal homepage
4,373
Views
4
CrossRef citations to date
0
Altmetric
Editorial

Triple reuptake inhibitors (TRIs): do they promise us a rose garden?

Samet KoseMD, PhD, Assoc. Prof. of Psychiatry, Editor-in-Chief, Psychiatry & Clinical Psychopharmacology, Academic Editor of Psychiatry and Behavioral Sciences, Franklin, TN, USACorrespondence[email protected]
ORCID Iconhttp://orcid.org/0000-0003-0841-004X
ORCID Icon &
Mesut CetinPsychiatry &Clinical Psychopharmacology and Psychiatry and Behavioral Sciences, Istanbul, TurkeyORCID Iconhttp://orcid.org/0000-0002-6378-5701
ORCID Icon
Pages 119-122 | Published online: 20 Mar 2018

References

  • Kessler RC, Bromet EJ. The epidemiology of depression across cultures. Annu Rev Public Health. 2013;34:119–138. doi: 10.1146/annurev-publhealth-031912-114409
  • Skolnick P, Krieter P, Tizzano J, et al. Preclinical and clinical pharmacology of DOV 216,303, a “triple” reuptake inhibitor. CNS Drug Rev. 2006;12(2):123–134. doi: 10.1111/j.1527-3458.2006.00123.x
  • Naranjo CA, Tremblay LK, Busto UE. The role of the brain reward system in depression. Prog Neuropsychopharmacol Biol Psychiatry. 2001;25(4):781–823. doi: 10.1016/S0278-5846(01)00156-7
  • Hasler G, Drevets WC, Manji HK, et al. Discovering endophenotypes for major depression. Neuropsychopharmacology. 2004;29(10):1765–1781. doi: 10.1038/sj.npp.1300506
  • Ressler KJ, Mayberg HS. Targeting abnormal neural circuits in mood and anxiety disorders: from the laboratory to the clinic. Nat Neurosci. 2007;10(9):1116–1124. doi: 10.1038/nn1944
  • Malhi GS, Berk M. Does dopamine dysfunction drive depression? Acta Psychiatr Scand Suppl. 2007;115:116–124. doi: 10.1111/j.1600-0447.2007.00969.x
  • Millan MJ. Dual- and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugs. Neurotherapeutics. 2009;6(1):53–77. doi: 10.1016/j.nurt.2008.10.039
  • Prins J, Olivier B, Korte SM. Triple reuptake inhibitors for treating subtypes of major depressive disorder: the monoamine hypothesis revisited. Expert Opin Investig Drugs. 2011;20(8):1107–1130. doi: 10.1517/13543784.2011.594039
  • Stotz G, Woggon B, Angst J. Psychostimulants in the therapy of treatment-resistant depression review of the literature and findings from a retrospective study in 65 depressed patients. Dialogues Clin Neurosci. 1999;1(3):165–174.
  • Skolnick P, Popik P, Janowsky A, et al. Antidepressant-like actions of DOV 21,947: a “triple” reuptake inhibitor. Eur J Pharmacol. 2003;461(2–3):99–104. doi: 10.1016/S0014-2999(03)01310-4
  • Tran P, Skolnick P, Czobor P, et al. Efficacy and tolerability of the novel triple reuptake inhibitor amitifadine in the treatment of patients with major depressive disorder: a randomized, double-blind, placebo-controlled trial. J Psychiatr Res. 2012;46(1):64–71. doi: 10.1016/j.jpsychires.2011.09.003
  • Learned S, Graff O, Roychowdhury S, et al. Efficacy, safety, and tolerability of a triple reuptake inhibitor GSK372475 in the treatment of patients with major depressive disorder: two randomized, placebo- and active-controlled clinical trials. J Psychopharmacol. 2012;26(5):653–662. doi: 10.1177/0269881111424931
  • Hauser RA, Salin L, Juhel N, et al. Randomized trial of the triple monoamine reuptake inhibitor NS2330 (tesofensine) in early Parkinson’s disease. Mov Disord. 2007;22(3):359–365. doi: 10.1002/mds.21258
  • Nutt D, Demyttenaere K, Janka Z, et al. The other face of depression, reduced positive affect: the role of catecholamines in causation and cure. J Psychopharmacol. 2007;21:461–471. doi: 10.1177/0269881106069938
  • Parker G. Is the diagnosis of melancholia important in shaping clinical management? Curr Opin Psychiatry. 2007;20:197–201. doi: 10.1097/YCO.0b013e3280ad43f0
  • Goldstein BJ, Goodnick PJ. Selective serotonin reuptake inhibitors in the treatment of affective disorders – III. Tolerability, safety and pharmacoeconomics. J Psychopharmacol. 1998;12:S55–S88. Dwoskin et al., 2006; . doi: 10.1177/0269881198012003041
  • Basile AS, Janowsky A, Golembiowska K, et al. Characterization of the antinociceptive actions of bicifadine in models of acute, persistent, and chronic pain. J Pharmacol Exp Ther. 2007;321(3):1208–1225. doi: 10.1124/jpet.106.116483
  • Thatte U. NS2330 (Neurosearch). Curr Opin Investig Drugs. 2001;2:1592–1594.
  • Zhang R, Li X, Shi Y, et al. The effects of LPM570065, a novel triple reuptake inhibitor, on extracellular serotonin, dopamine and norepinephrine levels in rats. PLoS One. 2014;9(3):e91775. doi: 10.1371/journal.pone.0091775
  • Guiard BP, El Mansari M, Merali Z, et al. Functional interactions between dopamine, serotonin and norepinephrine neurons: an invivo electrophysiological study in rats with monoaminergic lesions. Int J Neuropsychopharmacol. 2008;11:625–639. doi: 10.1017/S1461145707008383
  • McMillen BA, Shank JE, Jordan KB, et al. Effect of DOV 102,677 on the volitional consumption of ethanol by Myers’ high ethanol-preferring rat. Alcohol Clin Exp Res. 2007;31(11):1866–1871. doi: 10.1111/j.1530-0277.2007.00513.x
  • Brady LS, Insel TR. Translating discoveries into medicine: psychiatric drug development in 2011. Neuropsychopharmacol Rev. 2012;37:281–283. doi: 10.1038/npp.2011.106
  • Russo SJ, Nestler EJ. The brain reward circuitry in mood disorders. Nat Rev. 2013;14:609–625. doi: 10.1038/nrn3381

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.